Pacific Biosciences of California, Inc. (PACB)
Pacific Biosciences (PACB) Upgraded to Strong Buy: Here's What You Should Know
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Pacific Biosciences of California (PACB) Outperforms Broader Market: What You Need to Know
Pacific Biosciences of California (PACB) closed at $1.18 in the latest trading session, marking a +1.72% move from the prior day.
Here's Why You Should Add PacBio Stock to Your Portfolio Now
PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset sales cycle delays and drive 2025 growth.
All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PacBio Stock Slips Despite New China Distribution Deal With Haorui
PACB expands reach in China through Haorui Gene partnership, bringing HiFi sequencing to new clinical labs and boosting precision medicine access nationwide.
PACB Stock May Rise Following the Deal With Chulalongkorn University
PacBio and Chulalongkorn University launch Asia Pacific's first population-scale HiFi WGS newborn screening program, advancing precision medicine in Thailand.
PacBio Stock Down Despite Q1 Earnings & Revenue Beat Estimates
Despite strong Service and other revenues, PACB reports soft first-quarter 2025 results partly due to lower Revio system shipments.
Pacific Biosciences (PACB) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pacific Biosciences of California, Inc. (PACB) Q1 2025 Earnings Call Transcript
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Todd Friedman - Senior Director, Finance & Investor Relations Christian Henry - President & Chief Executive Officer Jim Gibson - Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research David Westenberg - Piper Sandler William Ruby - TD Cowen Operator Good afternoon, everyone. And welcome to the PacBio First Quarter 2025 Earnings Conference Call.
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.26 per share a year ago.
Pacific Biosciences of California (PACB) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.11, marking a -1.77% move from the previous day.
Pacific Biosciences of California (PACB) Flat As Market Gains: What You Should Know
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.17, marking no change from the previous day.
